PLYX (Polaryx Therapeutics) Operating Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYX Polaryx Therapeutics Inc PLYX
13 GF Score
Price $2.26
View Full Analysis

What is Polaryx Therapeutics Operating Margin %?

Polaryx Therapeutics PLYX +2.73% 13 Operating Margin % is 0.00% as of Mar. 2026. GuruFocus rates PLYX with a GF Score™ of 13/100. Among 939 Biotechnology companies, Polaryx Therapeutics ranks worse than 106496.17% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Polaryx Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-1.96 Mil. Polaryx Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Polaryx Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Polaryx Therapeutics's Operating Margin % or its related term are showing as below:


PLYX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.77
* Ranked among companies with meaningful Operating Margin % only.

Polaryx Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Polaryx Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-1.96 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.73 Mil.


Polaryx Therapeutics  (NAS:PLYX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Polaryx Therapeutics Operating Margin % Related Terms


Polaryx Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Polaryx Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polaryx Therapeutics Operating Margin % Chart

Polaryx Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Operating Margin %
0.00 0.00 0.00

Polaryx Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PLYX vs GUTS, NTHI, PEPG: Operating Margin % Comparison

For the Biotechnology subindustry, Polaryx Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Polaryx Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Polaryx Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Polaryx Therapeutics's Operating Margin % falls into.


PLYX
13GF Score
Polaryx Therapeutics Inc PLYX
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Polaryx Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-7.821 / 0
= %

Polaryx Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-1.958 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Polaryx Therapeutics (PLYX) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Polaryx Therapeutics and its competitors. According to the industry distribution chart, Polaryx Therapeutics ranks #999999 out of 939 companies in the Biotechnology industry.
Is Polaryx Therapeutics' Operating Margin % too high?
Polaryx Therapeutics' current Operating Margin % is 0.00%. Based on the distribution chart, Polaryx Therapeutics ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' Operating Margin % compare to GUTS and NTHI?
According to the Biotechnology industry distribution chart, Polaryx Therapeutics ranks #999999 out of 939 companies for Operating Margin %. This places Polaryx Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for PLYX

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price